Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript) | seekingalpha.com • |
Biocept to Hold Business Update Conference Call on August 30, 2023 | businesswire.com • |
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole | investorplace.com • |
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference | proactiveinvestors.com • |
Biocept appoints Antonino Morales as president and chief executive officer | proactiveinvestors.com • |
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023 | businesswire.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-11-20 | 2023-09 | 0 | N/A | N/A | N/A |
2023-05-10 | 2023-03 | 0 | N/A | N/A | N/A |
2023-04-17 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-21 | 2022-09 | -4.8 | N/A | N/A | N/A |
2022-11-10 | 2022-06 | 0 | N/A | N/A | N/A |
2022-05-23 | 2022-03 | -7.21 | N/A | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-12-08 | HALE DAVID F | Director | 0.00 | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Anson Funds Management LP | 44.86K | 54.28K | 1.71% |
2023-06-29 | Boothbay Fund Management, LLC | 23.53K | 28.47K | 0.90% |
2023-06-29 | Tower Research Capital LLC (TRC) | 5.39K | 6.52K | 0.21% |
2023-06-29 | Blackrock Inc. | 5.26K | 6.37K | 0.20% |
2023-06-29 | Acadian Asset Management. LLC | 247.00 | 298.00 | 0.01% |
2023-06-29 | Group One Trading, L.P. | 270.00 | 326.00 | 0.01% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 4.43K | 5.37K | 0.17% |
2023-05-30 | Fidelity Extended Market Index Fund | 2.95K | 6.38K | 0.11% |
2023-05-30 | Fidelity Series Total Market Index Fund | 644.00 | 1.39K | 0.02% |
2023-05-30 | Fidelity Total Market Index Fund | 488.00 | 1.05K | 0.02% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 189.00 | 408.00 | 0.01% |
Split | Date |
---|---|
1 : 30 | 2023-05-17 |
1 : 10 | 2020-09-08 |
1 : 30 | 2018-07-10 |
1 : 3 | 2016-09-29 |
-
Just now fucking hearing another offering immenant
-
Finally got out lost half my money but I’m done letting this company rob me
-
The piece of shit ceo makes the split decision months before needed then waits for stock to drop 50% he gotta go if it’s ever gonna work he blows at his job
-
We should all just take the hit this piece shit ceo deserves to lose this company instead stealing everyone money every few months scumbag
-
You didnt get it? They do reverse split that high so every day will be -.20$ and 11th day down under 1$
-
Is there anything that can be done or is the ceo just totally the worst ceo milling this company as long as they can do r/s till no more money
-
Fucking crooks
-
Authorization for the reverse stock split was approved by the Companys stockholders at Biocepts 2020 Annual Meeting of Stockholders. The objective of the reverse stock split is to increase the market price for the Companys common stock to, among things, enable the Company to regain compliance with the $1.00 minimum bid price requirement under applicable Nasdaq Listing Rules.
As a result of the reverse stock split, each ten pre-split shares of common stock outstanding will automatically combine and convert to one issued and outstanding share of common stock without any action on the part of the stockholder. No fractional shares of common stock will be issued to any shareholders in connection with the reverse stock split. Holders of record will receive a cash payment in lieu of fractional shares.
Stockholders of record will receive information regarding their share ownership following the reverse stock split from the Company's transfer agent, Continental Stock Transfer & Trust. Continental Stock Transfer & Trust can be reached at (212) 509-4000.
For additional information regarding the reverse stock split, please refer to Biocepts Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 4, 2020.
-
It will down more after the split
-
This company doing split every 2 years lol it heading down under 50 cent again after
-
Fucking crooks
-
This drop is all because of the ceo announcement of rs which could have waited months
-
Nobody is trading this stock
-
The price didn’t even move a penny
-
This company will never make it they been around for decade still can’t make it fire the ceo
-
I sold everything fuck this piece of poop
-
Why not moving??? This stock has concrete holding it down
-
Finally after all this roller coaster shit MERGER IMMINENT!!!!!!!!! I fucking knew it !!!!$$$$$$$$$$$$$$
-
Fucking ceo put out something this company is gonna go bust dumb ass
-
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)
seekingalpha.com • -
Biocept to Hold Business Update Conference Call on August 30, 2023
businesswire.com • -
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
investorplace.com • -
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference
proactiveinvestors.com • -
Biocept appoints Antonino Morales as president and chief executive officer
proactiveinvestors.com • -
Why Is Biocept (BIOC) Stock Down 42% Today?
investorplace.com • -
Biocept shares to commence trading on split-adjusted basis
proactiveinvestors.com • -
Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Biocept reports 176% year-over-year jump in orders for CNSide assay
proactiveinvestors.com • -
Biocept adds CPA Quyen Dao-Haddock to board, bringing extensive financial acumen to audit committee
proactiveinvestors.com • -
Biocept to use CNSide assay in study looking at biomarkers in patients with metastatic breast cancer
proactiveinvestors.com • -
Biocept to Hold Business Strategy Conference Call Today
businesswire.com • -
Biocept sees 1Q net revenue rise 12% driven by its coronavirus testing services
proactiveinvestors.com • -
Biocept, Inc. says coronavirus testing drove strong rise in full-year 2021 revenue
proactiveinvestors.com • -
Biocept reports unaudited net revenue of $61.2 million for 2021
proactiveinvestors.com • -
Biocept appoints Samuel Riccitelli as its interim CEO and Antonino Morales as interim CFO
proactiveinvestors.com • -
Biocept appoints Darrell Taylor as its new chief compliance officer
proactiveinvestors.com • -
Biocept says demand for its COVID-19 RT-PCR testing increases in 2022 amid Omicron variant surge
proactiveinvestors.com • -
Biocept launches single test for COVID-19 and Influenza as cases rise during flu season
proactiveinvestors.com • -
Biocept sees profitability in third quarter thanks to increased RT-PCR COVID-19 testing
proactiveinvestors.com • -
7 of the Best Penny Stocks to Buy Coming Into Year-End
investorplace.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept reports profitability for the first half on back of increased COVID-19 testing
proactiveinvestors.com • -
Biocept appoints David Karlander as senior vice president of Commercial Operations
proactiveinvestors.com • -
Biocept bolsters board of directors and names Samuel D Riccitelli as new chairman
proactiveinvestors.com • -
Biocept joins the Russell Microcap Index
proactiveinvestors.com • -
Biocept Joins the Russell Microcap® Index
businesswire.com • -
Wall Street takes a turn for the worse as investors eye Fed
proactiveinvestors.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept makes coronavirus testing available for California's 116 community colleges
proactiveinvestors.com • -
Biocept launches its CNSide cerebrospinal fluid assay for early detection of metastatic brain cancer
proactiveinvestors.com • -
Biocept says its lab received to-date more than 350,000 coronavirus testing samples for processing
proactiveinvestors.com • -
Biocept: Record Revenues And Profits Support Speculative Buy
seekingalpha.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept: Q4 Earnings Insights
benzinga.com • -
Biocept to Participate in Three Virtual Investment Conferences in March
businesswire.com • -
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com • -
Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
prnewswire.com • -
Analyzing Teleflex (NYSE:TFX) & Viatar CTC Solutions (NYSE:VRTT)
thelincolnianonline.com •